Novo Nordisk study shows benefits of diabetes drug Xultophy

Novo Nordisk has announced the findings of a new clinical trial that offers further evidence of the benefits offered by its type 2 diabetes therapy Xultophy.

Data from the phase IIIb trial DUAL VII compared the efficacy and safety of the once-daily regimen with insulin glargine U100 in combination with insulin aspart at all main meals, after 26 weeks of treatment in 506 adults with type 2 diabetes.

Xultophy was shown to offer non-inferior performance in terms of controlling blood glucose levels, with a superior reduction of 89 percent in the rate of severe or blood glucose-confirmed symptomatic hypoglycaemic episodes.

Furthermore, people treated with Xultophy experienced weight loss of 0.9 kg, compared with weight gain of 2.6 kg for people treated with the basal-bolus regimen.

Mads Krogsgaard Thomsen, executive vice-president and chief science officer of Novo Nordisk, said: "We are excited about the results of DUAL VII, showing the important benefits Xultophy offers for people inadequately controlled on insulin glargine U100 as an alternative to intensification with basal-bolus therapy."

Xultophy has been approved in Europe since 2014 and offers a fixed-dose combination of the long-acting insulin degludec and the GLP-1 receptor agonist liraglutide.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.